Skip to main content

Adalimumab Dosage

Medically reviewed by Drugs.com. Last updated on Sep 17, 2024.

Applies to the following strengths: afzb 40 mg/0.8 mL; afzb 20 mg/0.4 mL; 80 mg/0.8 mL-40 mg/0.4 mL; 80 mg/0.8 mL; 40 mg/0.4 mL; 20 mg/0.2 mL; 10 mg/0.1 mL; 40 mg/0.8 mL; 10 mg/0.2 mL; 20 mg/0.4 mL; adbm 40 mg/0.8 mL; adbm 10 mg/0.2 mL; adbm 20 mg/0.4 mL; adbm 40 mg/0.4 mL; fkjp 40 mg/0.8 mL; fkjp 20 mg/0.4 mL; ryvk 40 mg/0.4 mL; atto 20 mg/0.2 mL; atto 40 mg/0.8 mL; atto 20 mg/0.4 mL; atto 10 mg/0.2 mL; atto 40 mg/0.4 mL; atto 80 mg/0.8 mL; adaz 40 mg/0.4mL; adaz 80 mg/0.8mL; adaz 20 mg/0.2mL; adaz 10 mg/0.1mL; adaz 80 mg/0.8mL-40 mg/0.4mL; aacf 40 mg/0.8 mL; aqvh 40 mg/0.8 ml; aaty 40 mg/0.4 mL; aaty 80 mg/0.8 mL; aaty 20 mg/0.2 mL; bwwd 40 mg/0.8 mL; bwwd 40 mg/0.4 mL; adaz 40 mg/0.8 mL

Usual Adult Dose for Rheumatoid Arthritis

40 mg subcutaneously every other week; some patients with RA not taking concomitant methotrexate may benefit from increasing the frequency to 40 mg every week

Comments:


Use: Rheumatoid Arthritis (RA): To reduce symptoms, induce major clinical response, inhibit the progression of structural damage, and improve physical function in adult patients with moderately to severely active RA alone or in combination with methotrexate or other nonbiologic disease-modifying anti-rheumatic drugs (DMARDs)

Usual Adult Dose for Ankylosing Spondylitis

40 mg subcutaneously every other week

Comments:


Uses:

Usual Adult Dose for Psoriatic Arthritis

40 mg subcutaneously every other week

Comments:


Uses:

Usual Adult Dose for Crohn's Disease - Acute


Comments:

Uses:

Usual Adult Dose for Crohn's Disease - Maintenance


Comments:

Uses:

Usual Adult Dose for Ulcerative Colitis


Comments:

Uses:

Usual Adult Dose for Plaque Psoriasis

80 mg subcutaneously once, followed by 40 mg subcutaneously every other week, starting one week after the initial dose

Comments:


Use: Plaque Psoriasis (Ps): For adult patients with moderate to severe chronic Ps who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate

Usual Adult Dose for Uveitis

80 mg subcutaneously once, followed by 40 mg subcutaneously every other week, starting one week after the initial dose

Use: Uveitis (UV): For noninfectious intermediate, posterior, and panuveitis

Usual Adult Dose for Hidradenitis Suppurativa


Comments:

Use: For the treatment of moderate to severe hidradenitis suppurativa (HS)

Usual Pediatric Dose for Juvenile Idiopathic Arthritis

2 years and older:
10 kg to less than 15 kg: 10 mg subcutaneously every other week
15 kg to less than 30 kg: 20 mg subcutaneously every other week
30 kg or greater: 40 mg subcutaneously every other week

Comments:


Use: Juvenile Idiopathic Arthritis (JIA): To reduce symptoms of moderately to severely active polyarticular JIA in patients 2 years older; this drug can be used alone or in combination with methotrexate

Usual Pediatric Dose for Crohn's Disease - Acute

6 years and older:
17 kg to less than 40 kg: 80 mg subcutaneously on Day 1, followed by 40 mg subcutaneously 2 weeks later (Day 15), then 20 mg subcutaneously every other week
40 kg or greater: 160 mg subcutaneously on Day 1, followed by 80 mg subcutaneously 2 weeks later (Day 15), then 40 mg subcutaneously every other week

Comments:


Use: Pediatric Crohn's Disease (CD): To reduce symptoms and induce and maintain remission in patients 6 years and older with moderately to severely active CD who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate

Usual Pediatric Dose for Crohn's Disease - Maintenance

6 years and older:
17 kg to less than 40 kg: 80 mg subcutaneously on Day 1, followed by 40 mg subcutaneously 2 weeks later (Day 15), then 20 mg subcutaneously every other week
40 kg or greater: 160 mg subcutaneously on Day 1, followed by 80 mg subcutaneously 2 weeks later (Day 15), then 40 mg subcutaneously every other week

Comments:


Use: Pediatric Crohn's Disease (CD): To reduce symptoms and induce and maintain remission in patients 6 years and older with moderately to severely active CD who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate

Usual Pediatric Dose for Uveitis

2 years and older:
10 kg to less than 15 kg: 10 mg subcutaneously every other week
15 kg to less than 30 kg: 20 mg subcutaneously every other week
30 kg or greater: 40 mg subcutaneously every other week

Comments:


Use: Uveitis (UV): For non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older

Usual Pediatric Dose for Hidradenitis Suppurativa

12 years and older:
30 kg to less than 60 kg: 80 mg subcutaneously initially on Day 1, then 40 mg subcutaneously on Day 8, then 40 mg subcutaneously every other week
60 kg or greater: 160 mg subcutaneously initially on Day 1 (given in 1 day or split over 2 consecutive days), then 80 mg subcutaneously on Day 15, then 40 mg subcutaneously on Day 29, then 40 mg subcutaneously every week

Comments:


Use: For the treatment of moderate to severe hidradenitis suppurativa (HS) in patients 12 years of age and older

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNINGS:


CONTRAINDICATIONS:

Rheumatoid Arthritis (RA)/Psoriatic Arthritis (PsA)/Ankylosing Spondylitis (AS)/Ulcerative Colitis (UC)/Plaque Psoriasis (Ps): Safety and effectiveness have not been established in patients younger than 18 years.

Consult WARNINGS section of additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

General:

Monitoring:

Patient advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.